Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Heloisa de Andrade Carvalho is active.

Publication


Featured researches published by Heloisa de Andrade Carvalho.


Radiotherapy and Oncology | 2014

Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis.

Gustavo Nader Marta; Valter Silva; Heloisa de Andrade Carvalho; Fernando Freire Arruda; Samir Abdallah Hanna; Rafael Gadia; João Luis Fernandes da Silva; Sebastião Francisco Miranda Correa; Carlos Eduardo Cintra Vita Abreu; Rachel Riera

BACKGROUND AND PURPOSE Intensity-modulated radiation therapy (IMRT) provides the possibility of dose-escalation with better normal tissue sparing. This study was performed to assess whether IMRT can improve clinical outcomes when compared with two-dimensional (2D-RT) or three-dimensional conformal radiation therapy (3D-CRT) in patients with head and neck cancer. METHODS AND MATERIALS Only prospective phase III randomized trials comparing IMRT with 2D-RT or 3D-CRT were eligible. Combined surgery and/or chemotherapy were allowed. Two authors independently selected and assessed the studies regarding eligibility criteria and risk of bias. RESULTS Five studies were selected. A total of 871 patients were randomly assigned for 2D-RT or 3D-CRT (437), versus IMRT (434). Most patients presented with nasopharyngeal cancers (82%), and stages III/IV (62.1%). Three studies were classified as having unclear risk and two as high risk of bias. A significant overall benefit in favor of IMRT was found (hazard ratio - HR=0.76; 95% CI: 0.66, 0.87; p<0.0001) regarding xerostomia scores grade 2-4, with similar loco-regional control and overall survival. CONCLUSIONS IMRT reduces the incidence of grade 2-4 xerostomia in patients with head and neck cancers without compromising loco-regional control and overall survival.


Radiotherapy and Oncology | 2015

Accelerated partial irradiation for breast cancer: Systematic review and meta-analysis of 8653 women in eight randomized trials

Gustavo Nader Marta; Cristiane R Macedo; Heloisa de Andrade Carvalho; Samir Abdallah Hanna; João Luis Fernandes da Silva; Rachel Riera

BACKGROUND AND PURPOSE Accelerated partial breast irradiation (APBI) is the strategy that allows adjuvant treatment delivery in a shorter period of time in smaller volumes. This study was undertaken to assess the effectiveness and outcomes of APBI in breast cancer compared with whole-breast irradiation (WBI). MATERIAL AND METHODS Systematic review and meta-analysis of randomized controlled trials of WBI versus APBI. Two authors independently selected and assessed the studies regarding eligibility criteria. RESULTS Eight studies were selected. A total of 8653 patients were randomly assigned for WBI versus APBI. Six studies reported local recurrence outcomes. Two studies were matched in 5 years and only one study for different time of follow-up. Meta-analysis of two trials assessing 1407 participants showed significant difference in the WBI versus APBI group regarding the 5-year local recurrence rate (HR=4.54, 95% CI: 1.78-11.61, p=0.002). Significant difference in favor of WBI for different follow-up times was also found. No differences in nodal recurrence, systemic recurrence, overall survival and mortality rates were observed. CONCLUSIONS APBI is associated with higher local recurrence compared to WBI without compromising other clinical outcomes.


Histopathology | 2011

Immunohistochemical analysis of p53, APE1, hMSH2 and ERCC1 proteins in actinic cheilitis and lip squamous cell carcinoma

Ludmilla Regina de Souza; Thiago Fonseca-Silva; Camila Santos Pereira; Erivelton Pereira Santos; Lucianne Maia Costa Lima; Heloisa de Andrade Carvalho; Ricardo Santiago Gomez; André Luiz Sena Guimarães; Alfredo Maurício Batista de Paula

Souza L R, Fonseca‐Silva T, Pereira C S, Santos E P, Lima L C, Carvalho H A, Gomez R S, Guimarães A L S & De Paula A M B
(2011) Histopathology58, 352–360
Immunohistochemical analysis of p53, APE1, hMSH2 and ERCC1 proteins in actinic cheilitis and lip squamous cell carcinoma


International Braz J Urol | 2012

The role of radiotherapy in urinary bladder cancer: current status.

Gustavo Nader Marta; Samir Abdallah Hanna; Rafael Gadia; Sebastião Francisco Miranda Correa; João Luis Fernandes da Silva; Heloisa de Andrade Carvalho

The role of radiotherapy (RT) in the treatment of urinary bladder cancer has undergone several modifications along the last decades. In the beginning, definitive RT was used as treatment in an attempt to preserve the urinary bladder; however, the results were poor compared to those of radical surgery. Recently, many protocols have been developed supporting the use of multi-modality therapy, and the concept of organ preservation began to be reconsidered. Although phase III randomized clinical studies comparing radical cystectomy with bladder preservation therapies do not exist, the conservative treatment may present low toxicity and high indexes of complete response for selected patients. The aim of this study was to review the literature on the subject in order to situate RT in the current treatment of urinary bladder cancer.


Histopathology | 1997

Stereological estimates of the nuclear/cytoplasmic ratio and star volume on fibreoptic biopsies are of prognostic value for survival in a preliminary study of advanced squamous cell carcinoma of the lung.

Heloisa de Andrade Carvalho; Paulo Hilário Nascimento Saldiva; Tereza Takagaki; Vera Luiza Capelozzi

This study evaluated the role of morphometric and clinical parameters in establishing the prognosis of patients submitted to radiotherapy for advanced squamous cell carcinoma of the lung.


Radiologia Brasileira | 2005

A Tradescantia como bioindicador vegetal na monitoração dos efeitos clastogênicos das radiações ionizantes

Heloisa de Andrade Carvalho

The influence of chemical and physical agents (specially radiation) on the frequency of mutations has been widely studied by means of the analysis of changes observed in Tradescantia, a plant used as a bioindicator. The evaluation of these genetic changes may be performed both by detection of somatic mutations or chromosome abnormalities induced by mutagens that are present in the air, soil, or water. The results obtained from several studies support the use of Tradescantia for monitoring the effects of ionizing radiation. Studies of mutagenicity and chromosomal abnormalities may be carried out in future to compare the effects of other types of radiation, evaluation of the effects of the combined use of radiation and drugs or other chemical agents, and to monitor high risk environments.


Brachytherapy | 2013

High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: A quantitative assessment

Melissa Martins de Aquino Gorayeb; Marcelo Gervilla Gregório; Eduardo Quintino de Oliveira; Salim Aisen; Heloisa de Andrade Carvalho

PURPOSE This study was performed to objectively evaluate the effect of high-dose-rate endobronchial brachytherapy (HDREB) in symptom palliation of patients with malignant airway obstruction and treatment-related toxicity. METHODS AND MATERIALS Seventy-eight patients were treated with palliative intent according to a prospective observational protocol. HDREB was delivered in three fractions of 7.5 Gy at weekly or fortnightly intervals, associated or not with external beam irradiation. Most patients presented with lung cancer primaries and were treated because of lesions located in the trachea and/or main bronchi. Performance status, degree of obstruction, and symptom palliation were graded according to an objective score index, defined before and after HDREB at the last followup visit. Survival was considered from the end of HDREB for at least 3 years or until death. RESULTS Overall, there was a 70% improvement, with migration of patients from lower to higher performance status. Bronchial obstruction was improved in 73.4% of the patients. The symptom that presented the better response was hemoptysis (100% complete relief) followed by postobstructive pneumonia (80%), dyspnea (57.4%), and cough (33.9%). Median survival was 6 months and improved in patients with complete response at bronchoscopy (9 months). There were two (2.6%) cases of bronchial fistulae and eight cases (10.2%) of fatal hemoptysis. CONCLUSIONS HDREB is an excellent modality for palliating malignant airway obstruction resulting in quality of life improvement, with a good tolerance, patient compliance, and low rate of complications.


Clinics | 2005

High dose-rate brachytherapy as a treatment option in primary tracheal tumors

Heloisa de Andrade Carvalho; Viviane Rossi Figueiredo; Wilson Leite Pedreira; Salim Aisen

PURPOSE To present experience with high dose-rate endobronchial brachytherapy in the treatment of primary tracheal tumors. PATIENTS AND METHODS Four patients with nonresected primary tracheal tumors are presented: 2 cases of squamous cell carcinoma of the trachea, 1 of recurrent adenoid cystic carcinoma, and 1 with recurrent plasmacytoma. All received brachytherapy, alone or as a boost for primary irradiation, in 3 or 4 fractions of 7.5 Gy, calculated at a depth of 1 cm. Follow-up was considered to start from the end of brachytherapy. RESULTS Local control was achieved in all cases at the time of first bronchoscopic evaluation. Two patients with squamous cell carcinoma died at 6th and 33rd months after brachytherapy, respectively. The first had no evidence of disease, and the latter had local recurrence. The other 2 patients were alive after 64 and 110 months of follow-up, respectively, both with no evidence of disease. Tracheal stenosis developed in these 2 cases, 22 and 69 months after brachytherapy. Tracheal stent placement was needed only for the patient with an adenoid cystic carcinoma. CONCLUSIONS Endobronchial high dose-rate brachytherapy may be used for tracheal tumors, even as a boost for external beam irradiation, or in recurrences. Local control in 3 out of 4 patients indicates that individual cases may benefit from the treatment. Long-term survival may also be expected, mainly for tumors with adenoid cystic histology.


International Journal of Radiation Oncology Biology Physics | 2015

Brazil's Challenges and Opportunities

Fabio Ynoe de Moraes; Gustavo Nader Marta; Samir Abdallah Hanna; Elton Trigo Teixeira Leite; Robson Ferrigno; João Luis Fernandes da Silva; Heloisa de Andrade Carvalho

*Department of Radiation Oncology/Oncology Center, Hospital Sı́rio-Libanês, São Paulo, Brazil; yDepartment of Radiology and Oncology, Instituto do Cancêr do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; zDepartment of Radiation Oncology, Hospital Beneficiência Portuguesa, São Paulo, Brazil; xDepartment of Radiology and Oncology, Instituto de Radiologia do Hospital das Clı́nicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil


Histopathology | 2012

DNA repair gene excision repair cross complementing‐group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors

Lucianne Maia Costa Lima; Ludmilla Regina de Souza; Thiago Fonseca da Silva; Camila Santos Pereira; André Luiz Sena Guimarães; Alfredo Maurício Batista de Paula; Heloisa de Andrade Carvalho

Lima L M C, de Souza L R, da Silva T F, Pereira C S, Guimarães A L S, de Paula A M B & Carvalho H A 
(2012) Histopathology 60, 489–496
DNA repair gene excision repair cross complementing‐group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors

Collaboration


Dive into the Heloisa de Andrade Carvalho's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Salim Aisen

University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Gustavo Nader Marta

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Gustavo Nader Marta

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge